ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Has anyone tried trestolone acetate? About to start my experiment
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 29654" data-attributes="member: 3"><p>This compound is puzzling to me (I would really love to try it!). Yes, it shuts down LH, FSH and T but it provides the same sexual, mood and energy benefits as T.</p><p></p><p></p><p><strong>7α-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men - </strong></p><p></p><p>See more at: <a href="http://press.endocrine.org.ezproxyhost.library.tmc.edu/doi/full/10.1210/jcem.84.10.6028#sthash.ZsjugTPp.dpuf" target="_blank">http://press.endocrine.org.ezproxyhost.library.tmc.edu/doi/full/10.1210/jcem.84.10.6028#sthash.ZsjugTPp.dpuf</a></p><p></p><p>Abstract</p><p></p><p></p><p>The synthetic steroid 7α-methyl-19-nortestosterone (MENT) is a potent androgen that is resistant to 5α-reductase. It thus has decreased activity at the prostate and may have advantages over testosterone-based regimens in long term treatment or as part of a male contraceptive. Administration to eugonadal men results in suppression of gonadotropins, but its ability to support androgen-dependent behavior has not been investigated. For sustained release administration, MENT acetate was used, because its diffusion characteristics were more suitable for use in implants. However, upon release the acetate is rapidly hydrolyzed, and MENT is the biologically active moiety in circulation. We studied the effects of MENT on sexual interest and activity, spontaneous erection, and mood states in comparison with testosterone enanthate (TE) in 20 Caucasian and Chinese hypogonadal men recruited in Edinburgh and Hong Kong (n = 10 in each center). Outcomes were measured using a combination of daily diaries, semistructured interviews, and questionnaires. Nocturnal penile tumescence (NPT) was also recorded in the Edinburgh group. <strong>After withdrawal of androgen replacement treatment (wash-out phase) for a minimum of 6 weeks, subjects were randomized to two groups in a cross-over design. Drug treatment regimens were of 6-week duration and consisted of two implants, each containing 115 mg MENT acetate, inserted sc into the upper arm and removed after 6 weeks and two injections of TE (200 mg, im) 3 weeks apart. </strong>MENT treatment resulted in stable plasma MENT concentrations of 1.4 ± 0.1 nmol/L after 3 weeks and 1.3 ± 0.1 nmol/L after 6 weeks (mean ± sem; all men). Nadir testosterone concentrations were 3.6 ± 0.6 nmol/L at the end of the wash-out phase and 9.4 ± 0.6 nmol/L 3 weeks after each injection. There were no differences in hormone concentrations between centers. There were no adverse toxicological effects.</p><p>There were only minor differences between the two treatments. <strong>Both MENT and TE treatment resulted in significant increases in sexual interest and activity, spontaneous erection (both by self-report and NPT measurement), and increases in positive moods, with decreases in negative moods in the Edinburgh group. In the Hong Kong group, both treatments increased waking erection, with a trend toward increased sexual interest and activity. </strong>Mood states appeared to be less affected during the wash-out phase than in Edinburgh men and showed no significant response to either treatment. <strong>These results demonstrate that MENT has similar effects on sexual activity and mood states as testosterone in hypogonadal men.</strong> As NPT is a physiological androgen-dependant outcome, these data provide further evidence for the androgenicity of MENT. The lack of detected effect of either androgen in Hong Kong men other than on waking erection illustrates the importance of the cultural context of symptomatology and its measurement. The appropriate dose of MENT remains to be determined, but these results support its development as a potential androgen replacement therapy.</p><p></p><p></p><p>ANDROGEN therapy is predominantly used for replacement in primary hypogonadism. Other potential indications include the treatment of secondary hypogonadism, particularly that associated with aging, and as a hormonal male contraceptive that will involve long term treatment of large numbers of healthy men (1). Recent developments in androgen administration (2, 3, 4, 5) have addressed some of the problems with previous preparations, but are all based on treatment with testosterone. The use of synthetic androgens allows the possibility of more specific effects tailored to particular indications. 7α-Methyl-19-nortestosterone (MENT) is a synthetic androgen that is approximately 10 times more potent than testosterone in anabolic bioassays and as a suppressor of gonadotropin secretion, but it is resistant to 5α-reduction. It therefore has relatively low potency in bioassays in which the testosterone-amplifying activity of 5α-reductase is important, such as stimulation of prostate size in castrate animals (6, 7, 8). This may be an advantage in long term treatment (9). Human data on the androgenic effects of MENT are, however, currently limited to the demonstration of the ability of repeated injections to suppress gonadotropin secretion in normal men (10) and early studies of masculinizing effects in female breast cancer patients (11).</p><p>MENT is not bound by sex hormone-binding globulin and is cleared rapidly from the circulation (12). MENT acetate (MENT Ac) can, however, be prepared in the form of implants for subdermal insertion, thus giving the potential for long term replacement therapy or treatment. Although MENT has been demonstrated to restore sexual behavior in castrate male mice (13), there are no data on the ability of this steroid to provide androgen replacement in men. This study was therefore performed to assess the effects of MENT Ac-containing implants on sexual function and mood in hypogonadal men.</p><p></p><p>- See more at: <a href="http://press.endocrine.org.ezproxyhost.library.tmc.edu/doi/full/10.1210/jcem.84.10.6028#sthash.ZsjugTPp.dpuf" target="_blank">http://press.endocrine.org.ezproxyhost.library.tmc.edu/doi/full/10.1210/jcem.84.10.6028#sthash.ZsjugTPp.dpuf</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 29654, member: 3"] This compound is puzzling to me (I would really love to try it!). Yes, it shuts down LH, FSH and T but it provides the same sexual, mood and energy benefits as T. [B]7α-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men - [/B] See more at: [URL]http://press.endocrine.org.ezproxyhost.library.tmc.edu/doi/full/10.1210/jcem.84.10.6028#sthash.ZsjugTPp.dpuf[/URL] Abstract The synthetic steroid 7α-methyl-19-nortestosterone (MENT) is a potent androgen that is resistant to 5α-reductase. It thus has decreased activity at the prostate and may have advantages over testosterone-based regimens in long term treatment or as part of a male contraceptive. Administration to eugonadal men results in suppression of gonadotropins, but its ability to support androgen-dependent behavior has not been investigated. For sustained release administration, MENT acetate was used, because its diffusion characteristics were more suitable for use in implants. However, upon release the acetate is rapidly hydrolyzed, and MENT is the biologically active moiety in circulation. We studied the effects of MENT on sexual interest and activity, spontaneous erection, and mood states in comparison with testosterone enanthate (TE) in 20 Caucasian and Chinese hypogonadal men recruited in Edinburgh and Hong Kong (n = 10 in each center). Outcomes were measured using a combination of daily diaries, semistructured interviews, and questionnaires. Nocturnal penile tumescence (NPT) was also recorded in the Edinburgh group. [B]After withdrawal of androgen replacement treatment (wash-out phase) for a minimum of 6 weeks, subjects were randomized to two groups in a cross-over design. Drug treatment regimens were of 6-week duration and consisted of two implants, each containing 115 mg MENT acetate, inserted sc into the upper arm and removed after 6 weeks and two injections of TE (200 mg, im) 3 weeks apart. [/B]MENT treatment resulted in stable plasma MENT concentrations of 1.4 ± 0.1 nmol/L after 3 weeks and 1.3 ± 0.1 nmol/L after 6 weeks (mean ± sem; all men). Nadir testosterone concentrations were 3.6 ± 0.6 nmol/L at the end of the wash-out phase and 9.4 ± 0.6 nmol/L 3 weeks after each injection. There were no differences in hormone concentrations between centers. There were no adverse toxicological effects. There were only minor differences between the two treatments. [B]Both MENT and TE treatment resulted in significant increases in sexual interest and activity, spontaneous erection (both by self-report and NPT measurement), and increases in positive moods, with decreases in negative moods in the Edinburgh group. In the Hong Kong group, both treatments increased waking erection, with a trend toward increased sexual interest and activity. [/B]Mood states appeared to be less affected during the wash-out phase than in Edinburgh men and showed no significant response to either treatment. [B]These results demonstrate that MENT has similar effects on sexual activity and mood states as testosterone in hypogonadal men.[/B] As NPT is a physiological androgen-dependant outcome, these data provide further evidence for the androgenicity of MENT. The lack of detected effect of either androgen in Hong Kong men other than on waking erection illustrates the importance of the cultural context of symptomatology and its measurement. The appropriate dose of MENT remains to be determined, but these results support its development as a potential androgen replacement therapy. ANDROGEN therapy is predominantly used for replacement in primary hypogonadism. Other potential indications include the treatment of secondary hypogonadism, particularly that associated with aging, and as a hormonal male contraceptive that will involve long term treatment of large numbers of healthy men (1). Recent developments in androgen administration (2, 3, 4, 5) have addressed some of the problems with previous preparations, but are all based on treatment with testosterone. The use of synthetic androgens allows the possibility of more specific effects tailored to particular indications. 7α-Methyl-19-nortestosterone (MENT) is a synthetic androgen that is approximately 10 times more potent than testosterone in anabolic bioassays and as a suppressor of gonadotropin secretion, but it is resistant to 5α-reduction. It therefore has relatively low potency in bioassays in which the testosterone-amplifying activity of 5α-reductase is important, such as stimulation of prostate size in castrate animals (6, 7, 8). This may be an advantage in long term treatment (9). Human data on the androgenic effects of MENT are, however, currently limited to the demonstration of the ability of repeated injections to suppress gonadotropin secretion in normal men (10) and early studies of masculinizing effects in female breast cancer patients (11). MENT is not bound by sex hormone-binding globulin and is cleared rapidly from the circulation (12). MENT acetate (MENT Ac) can, however, be prepared in the form of implants for subdermal insertion, thus giving the potential for long term replacement therapy or treatment. Although MENT has been demonstrated to restore sexual behavior in castrate male mice (13), there are no data on the ability of this steroid to provide androgen replacement in men. This study was therefore performed to assess the effects of MENT Ac-containing implants on sexual function and mood in hypogonadal men. - See more at: [URL]http://press.endocrine.org.ezproxyhost.library.tmc.edu/doi/full/10.1210/jcem.84.10.6028#sthash.ZsjugTPp.dpuf[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Basics & Questions
Has anyone tried trestolone acetate? About to start my experiment
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top